Literature DB >> 26043661

Structure-based virtual screening as a tool for the identification of novel inhibitors against Mycobacterium tuberculosis 3-dehydroquinate dehydratase.

Guilherme O Petersen1, Shalini Saxena2, Janupally Renuka2, Vijay Soni2, Perumal Yogeeswari2, Diogenes S Santos3, Cristiano V Bizarro4, Dharmarajan Sriram5.   

Abstract

3-Dehydroquinate dehydratase (DHQase), the third enzyme of the shikimate pathway, catalyzes the reversible reaction of 3-dehydroquinate into 3-dehydroshikimate. The aim of the present study was to identify new drug-like molecules as inhibitors for Mycobacterium tuberculosis DHQase employing structure-based pharmacophore modeling technique using an in house database consisting of about 2500 small molecules. Further the pharmacophore models were validated using enrichment calculations, and finally three models were employed for high-throughput virtual screening and docking to identify novel small molecules as DHQase inhibitors. Five compounds were identified, out of which, one molecule (Lead 1) showed 58% inhibition at 50μ M concentration in the Mtb DHQase assay. Chemical derivatives of the Lead 1 when tested evolved top two hits with IC50s of 17.1 and 31.5 μM as well as MIC values of 25 and 6.25 μg/mL respectively and no cytotoxicity up to 100 μM concentration.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DHQase; Drug discovery; Shikimate pathway; Tuberculosis; Virtual screening

Mesh:

Substances:

Year:  2015        PMID: 26043661     DOI: 10.1016/j.jmgm.2015.05.001

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  7 in total

Review 1.  Docking Screens for Novel Ligands Conferring New Biology.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Med Chem       Date:  2016-03-15       Impact factor: 7.446

2.  Rational design of drug-like compounds targeting Mycobacterium marinum MelF protein.

Authors:  Renu Dharra; Sakshi Talwar; Yogesh Singh; Rani Gupta; Jeffrey D Cirillo; Amit K Pandey; Mahesh Kulharia; Promod K Mehta
Journal:  PLoS One       Date:  2017-09-05       Impact factor: 3.240

3.  Molecular Quantum Similarity, Chemical Reactivity and Database Screening of 3D Pharmacophores of the Protein Kinases A, B and G from Mycobacterium tuberculosis.

Authors:  Alejandro Morales-Bayuelo
Journal:  Molecules       Date:  2017-06-21       Impact factor: 4.411

Review 4.  Predictive Power of In Silico Approach to Evaluate Chemicals against M. tuberculosis: A Systematic Review.

Authors:  Giulia Oliveira Timo; Rodrigo Souza Silva Valle Dos Reis; Adriana Françozo de Melo; Thales Viana Labourdette Costa; Pérola de Oliveira Magalhães; Mauricio Homem-de-Mello
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-16

Review 5.  Mycobacterium tuberculosis Shikimate Pathway Enzymes as Targets for the Rational Design of Anti-Tuberculosis Drugs.

Authors:  José E S Nunes; Mario A Duque; Talita F de Freitas; Luiza Galina; Luis F S M Timmers; Cristiano V Bizarro; Pablo Machado; Luiz A Basso; Rodrigo G Ducati
Journal:  Molecules       Date:  2020-03-11       Impact factor: 4.411

6.  Structure-Based Virtual Screening of Benzaldehyde Thiosemicarbazone Derivatives against DNA Gyrase B of Mycobacterium tuberculosis.

Authors:  Andiyappan Kistan; Balakrishnan Anna Benedict; Sundaramoorthy Vasanthan; Alphonse PremKumar; Malathi Kullappan; Jenifer Mallavarpu Ambrose; Vishnu Priya Veeraraghavan; Gayathri Rengasamy; Krishna Mohan Surapaneni
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-13       Impact factor: 2.629

Review 7.  Drug Discovery for Mycobacterium tuberculosis Using Structure-Based Computer-Aided Drug Design Approach.

Authors:  Murtala A Ejalonibu; Segun A Ogundare; Ahmed A Elrashedy; Morufat A Ejalonibu; Monsurat M Lawal; Ndumiso N Mhlongo; Hezekiel M Kumalo
Journal:  Int J Mol Sci       Date:  2021-12-09       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.